Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer.

Next Previous
Trial Profile

A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer.

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 03 May 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Varlilumab (Primary)
  • Indications Bladder cancer; Breast cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Urogenital cancer
  • Focus Adverse reactions
  • Sponsors Celldex Therapeutics Inc

    • Most Recent Events

    • 15 Mar 2017 Status changed from recruiting to discontinued.
    • 14 Mar 2017 According to a Celldex Therapeutics media release, company has decided not to advance the varlilumab/Tecentriq combination studies in renal cell carcinoma to Phase 2, due to cost-containment.
    • 08 Aug 2016 According to a Celldex Therapeutics media release, enrollment has been completed in the phase I dose-escalation portion and the company anticipates to initiate the phase II portion of the study in renal cell carcinoma in the third quarter of 2016.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top